Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Key transaction details include:
- Transaction Date: July 17, 2013
- Underlying Event: Notional re-investment of the dividend paid on July 11, 2013.
- Share Price: 1,742.50 pence per Ordinary Share; $52.91 per American Depositary Share (ADS).
- Participants: Increases in notional interests were recorded for 15 individuals, including Sir Andrew Witty (15,933.601 Ordinary Shares) and Dr. M M Slaoui (5,063.622 ADSs).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents the administrative increase in notional share holdings for plan participants following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It notes that notional dividends accrued will be paid out proportionally based on the percentage of holdings that vest after the relevant measurement period.
Investor Verification Points
- Verify the vesting schedule and measurement period for the 2009 Performance Share Plan to understand when these notional holdings may convert to actual equity.
- Confirm the dividend payment date of July 11, 2013, in the company's broader financial reports to contextualize the reinvestment price.
- Review the total number of shares outstanding to assess the dilution impact, if any, of these notional increases upon vesting.